SCHEMBL8086822

SCHEMBL8086822

C=C(Nc1cccc(OC)c1)c1ccc(N(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.55
NPC1 O15118 6/20 0.52
RAB9A P51151 6/20 0.52
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
KMT2A Q03164 2/20 0.52
TP53 P04637 2/20 0.52
PKM P14618 1/20 0.52
MAPT P10636 3/20 0.51
GAA P10253 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.50
MAPK1 P28482 1/20 0.50
CASP3 P42574 1/20 0.50
HTT P42858 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8071365 0.84 NPC1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL4251069 0.83 NPC1 (0.76) ROCK2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL8079371 0.81 NPC1 (0.65) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL8086791 0.80 NPC1 (0.51) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL8091906 0.79 NPC1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL13391762 0.77 KMT2A (0.69) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL5180476 0.76 NPC1 (0.64) ROCK2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4227376 0.76 MTNR1B (0.59) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL5180471 0.75 ROCK2 (0.53) ROCK2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL8086755 0.75 RAB9A (0.50) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed